Bruce J Kinon

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Am J Emerg Med 22:181-6. 2004
  2. pmc The burden of depressive symptoms in the long-term treatment of patients with schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland at Baltimore, School of Medicine, USA
    Schizophr Res 90:186-97. 2007
  3. doi Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46258, USA
    J Clin Psychopharmacol 28:601-7. 2008
  4. ncbi Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    Ann N Y Acad Sci 1032:295-6. 2004
  5. ncbi A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms
    Bruce J Kinon
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:157-62. 2006
  6. doi Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study
    Bruce J Kinon
    Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:392-400. 2008
  7. doi The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:544-9. 2008
  8. doi Placebo response in clinical trials with schizophrenia patients
    Bruce J Kinon
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Curr Opin Psychiatry 24:107-13. 2011
  9. doi Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Res 118:176-82. 2010
  10. pmc Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Bull 34:1163-71. 2008

Detail Information

Publications62

  1. ncbi Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Am J Emerg Med 22:181-6. 2004
    ..89 +/- 6.05 for haloperidol, P <.001). This study demonstrated that accelerated dose titration of oral olanzapine is as efficacious as oral haloperidol in reducing acute agitation in patients with schizophrenia...
  2. pmc The burden of depressive symptoms in the long-term treatment of patients with schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland at Baltimore, School of Medicine, USA
    Schizophr Res 90:186-97. 2007
    ..To prospectively measure the link between depressive symptoms and functional outcomes in the long-term treatment of people with schizophrenia...
  3. doi Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46258, USA
    J Clin Psychopharmacol 28:601-7. 2008
    ..Aripiprazole-treated patients had smaller increases in glucose and lipids, but no difference was observed between treatments in the proportion of patients experiencing categorical shifts in these measures...
  4. ncbi Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    Ann N Y Acad Sci 1032:295-6. 2004
    ....
  5. ncbi A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms
    Bruce J Kinon
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:157-62. 2006
    ..The objective of this study is to compare olanzapine with ziprasidone therapy in patients with schizophrenia or schizoaffective disorder and experiencing depressive symptoms...
  6. doi Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study
    Bruce J Kinon
    Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:392-400. 2008
    ....
  7. doi The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:544-9. 2008
    ..Early improvement in positive or depressive/anxiety symptoms is especially predictive of treatment persistence...
  8. doi Placebo response in clinical trials with schizophrenia patients
    Bruce J Kinon
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Curr Opin Psychiatry 24:107-13. 2011
    ..We present a current review of placebo response in clinical trials of schizophrenia...
  9. doi Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Res 118:176-82. 2010
    ..In this study, we assessed the effects of early response/non-response to an atypical antipsychotic across multiple outcome measures...
  10. pmc Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Bull 34:1163-71. 2008
    ..This study assessed the predictive accuracy of early nonresponse to treatment and its clinical, functional, and economic ramifications in the naturalistic treatment of predominately chronic outpatients treated for schizophrenia...
  11. ncbi Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:632-7. 2006
    ....
  12. pmc Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 35:581-90. 2010
    ....
  13. pmc Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Med 3:21. 2005
    ..Stopping antipsychotic treatment can interrupt improvement and exacerbate the illness. The reasons for discontinuing treatment during controlled clinical trials were analyzed to explore this phenomenon...
  14. ncbi Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:453-61. 2006
    ..Greater improvement in positive symptoms and a greater study completion rate may hold relevance to enhanced functional outcomes observed after OLZ therapy...
  15. ncbi Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia
    Douglas E Faries
    Eli Lilly and Co, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Curr Med Res Opin 24:1399-405. 2008
    ..Switching medications is common in the treatment of schizophrenia. This study examines the effectiveness of olanzapine therapy following a clinically warranted switch from risperidone during treatment of patients with schizophrenia...
  16. ncbi Bone loss associated with hyperprolactinemia in patients with schizophrenia
    Bruce J Kinon
    Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN
    Clin Schizophr Relat Psychoses 7:115-23. 2013
    ..The objective of this study was to determine the prevalence of low BMD in patients with schizophrenia treated with conventional antipsychotics or risperidone and to evaluate any potential relationship with treatment...
  17. pmc Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial
    Douglas Faries
    Eli Lilly and Company, Lilly Corporate Center, DC 5024, Indianapolis, IN 46285, USA
    BMC Med Res Methodol 12:142. 2012
    ....
  18. doi Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms
    Virginia L Stauffer
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 134:195-201. 2012
    ..This distinction, incorporating an evaluation of the presence of positive, affective, and extrapyramidal symptoms, may therefore not have prognostic implications for the responsiveness of patients' negative symptoms to treatment...
  19. pmc Predictors of switching antipsychotic medications in the treatment of schizophrenia
    Allen W Nyhuis
    Eli Lilly and Company, Indianapolis, IN USA
    BMC Psychiatry 10:75. 2010
    ..To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia...
  20. pmc Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
    BMC Psychiatry 5:3. 2005
    ..This study assessed the impact of acute treatment-emergent weight gain on clinical and functional outcomes of patients with schizophrenia by patient gender and antipsychotic treatment (olanzapine or haloperidol)...
  21. ncbi Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Res 102:230-40. 2008
    ..To test whether early onset of response to antipsychotic medications accurately predicts subsequent response in the treatment of patients with schizophrenia...
  22. ncbi Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic
    Haya Ascher-Svanum
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Psychopharmacol 19:110-7. 2005
    ..88, p 0.05). Treatment-emergent weight gain appears to be an important marker of symptom reduction, and may not be exclusively attributable to pharmacological perturbations...
  23. ncbi Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
    Virginia L Stauffer
    Eli Lilly and Company, Indianapolis, IN 46285 USA Electronic address
    Schizophr Res 150:434-41. 2013
    ..This study found no benefit of adjunctive LY2140023 versus PBO for negative symptoms in patients with schizophrenia receiving treatment with SOC. LY2140023 was generally well-tolerated in these patients. ..
  24. pmc Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
    Douglas E Faries
    US Statistics, Lilly USA, LLC, Indianapolis, IN, USA
    BMC Psychiatry 9:54. 2009
    ..The goal of this research was to assess the clinical and economic ramifications of switching antipsychotics during outpatient management of schizophrenia...
  25. doi Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods
    Lei Chen
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
    Schizophr Res 113:34-40. 2009
    ..Identify the optimal magnitude of response to antipsychotic medication at various early time points that best predicts subsequent non-response at 8 weeks...
  26. pmc Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 10:11. 2010
    ..This study assessed the prevalence of encounters with the criminal justice system, encounter types, and the estimated cost attributable to these encounters in the one-year treatment of persons with schizophrenia...
  27. doi Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis
    Virginia L Stauffer
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychiatry Res 187:42-8. 2011
    ..As had been seen in the treatment of patients with chronic schizophrenia, early non-response was a robust predictor of subsequent non-response in the treatment of patients with first-episode psychosis...
  28. ncbi Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Int J Neuropsychopharmacol 6:97-102. 2003
    ..05). Olanzapine orally disintegrating tablets were well-tolerated. Olanzapine orally disintegrating tablets may benefit acutely ill, non-compliant schizophrenic patients by facilitating acceptance of active antipsychotic drug therapy...
  29. ncbi Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    Prog Neuropsychopharmacol Biol Psychiatry 28:985-96. 2004
    ..The aim of this 8-month study was to determine if olanzapine treatment could lead to a significant and persistent reduction in preexisting TD...
  30. pmc Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
    Stephen J Ruberg
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 11:23. 2011
    ..To identify a simple decision tree using early symptom change to predict response to atypical antipsychotic therapy in patients with (Diagnostic and Statistical Manual, Fourth Edition, Text Revised) chronic schizophrenia...
  31. ncbi Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Psychoneuroendocrinology 28:69-82. 2003
    ..A discrimination of prolactin-sparing versus prolactin-elevating antipsychotic drugs may provide the clinician with treatment choices in order to avoid or mitigate hyperprolactinemia-associated morbidity...
  32. ncbi Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial
    Sandra L Tunis
    US Medical Division, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Value Health 9:77-89. 2006
    ....
  33. doi Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone
    Bonnie A Fijal
    Lilly USA, Indianapolis, IN 46285, USA
    J Clin Psychiatry 73:367-71. 2012
    ..We examined 6 single nucleotide polymorphisms (SNPs) previously reported to be associated with response to iloperidone therapy for association with response to risperidone therapy...
  34. pmc The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial
    Lei Chen
    Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 11:203. 2011
    ..In this exploratory study, we characterized the relationships among six clinical, functional, cognitive, and quality-of-life measures, identifying a parsimonious set of measurements...
  35. ncbi The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Am Med Dir Assoc 4:189-94. 2003
    ....
  36. ncbi Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation
    Robert W Baker
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285
    J Clin Psychopharmacol 23:342-8. 2003
    ..Rapid assessment and effective treatment are necessary to manage agitation and, potentially, to shorten the time to recovery...
  37. ncbi Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels
    Jonna Ahl
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    Ann N Y Acad Sci 1032:289-90. 2004
    ..Our findings indicate that sexual function improved with euprolactinemia in patients switched from treatment with prolactin-elevating antipsychotics to olanzapine...
  38. ncbi Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    Psychoneuroendocrinology 31:577-88. 2006
    ..Olanzapine treatment may offer sustained reduction in serum prolactin and improvement in sexual and reproductive comorbid symptoms in patients with schizophrenia who have treatment-emergent hyperprolactinemia...
  39. doi Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 30:286-9. 2010
    ..Early response to antipsychotic treatment discriminated AD from placebo. Reducing placebo-controlled clinical trials from 6 weeks to 2 to 4 weeks was found to be a viable option for efficacy identification in acutely ill patients...
  40. ncbi The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial
    Lei Chen
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 13:320. 2013
    ..This study assessed the temporal interplay between these two symptom domains and evaluated whether the improvements in these symptoms were inversely correlated or independent with each other...
  41. pmc Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study
    Virginia S Haynes
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 12:222. 2012
    ..This post-hoc analysis of a 3-year study compared the costs of mental health services and functional outcomes between individuals with schizophrenia who met or did not meet cross-sectional symptom remission at study enrollment...
  42. doi Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials
    Virginia Stauffer
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 130:11-9. 2011
    ..Most patients had modest and sustained improvements during atypical antipsychotic treatment, regardless of their baseline illness severity, representing a partial response to currently available treatments...
  43. doi Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 26:2403-10. 2010
    ..To identify reasons for discontinuation and continuation of antipsychotic medications in the treatment of schizophrenia from the patients' and their clinicians' perspectives...
  44. ncbi Dose response and atypical antipsychotics in schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    CNS Drugs 18:597-616. 2004
    ..Furthermore, the higher doses are not associated with a significantly increased incidence of adverse events. Further studies are clearly needed to fully characterise the dose-response relationships of atypical antipsychotics...
  45. ncbi Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 25:255-8. 2005
    ..By measuring the weight of patients during the first few weeks of olanzapine treatment and by assessing changes in appetite, clinicians may be able to identify those patients at risk for substantial weight gain...
  46. pmc Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis
    Virginia L Stauffer
    Neuroscience, Lilly USA, LLC, Indianapolis, IN 46285, USA
    BMC Psychiatry 9:12. 2009
    ..Identification of patient subgroups with different degrees of susceptibility to the effect of weight mitigating agents during olanzapine treatment may aid clinicians in treatment decisions...
  47. doi A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia
    Bruce J Kinon
    Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Psychopharmacol 31:349-55. 2011
    ..Additional efficacy, safety, and tolerability testing are needed...
  48. pmc Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy
    Xiaomei Peng
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Clinicoecon Outcomes Res 3:79-87. 2011
    ....
  49. ncbi Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study
    Haya Ascher-Svanum
    U S Outcomes Research, Eli Lilly and Co, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
    J Clin Psychiatry 69:1580-8. 2008
    ..The objective of this study was to compare the 3-year course of schizophrenia between persons with tardive dyskinesia (TD) and persons without TD on multiple outcome measures...
  50. ncbi Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, Indiana 46285, USA
    Ann N Y Acad Sci 1032:297-8. 2004
    ..Identified risk factors appear to be age and hyperprolactinemia for both females and males...
  51. pmc Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia
    Lei Chen
    Eli Lilly and Company, Indianapolis, IN, USA
    Neuropsychiatr Dis Treat 9:815-22. 2013
    ..This study identified subgroups of patients with schizophrenia who differed on their movement disorder profile and compared their treatment outcomes...
  52. doi Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies
    Mosun Ayan-Oshodi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 32:408-11. 2012
    ..There were no clinically significant changes in electroencephalograms in subjects receiving LY2140023 (n = 26). LY2140023 was generally well tolerated in healthy subjects...
  53. ncbi Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs
    Sandra L Tunis
    US Medical Division, Eli Lilly and Company, Indianapolis, Indiana, USA
    Pharmacoeconomics 22:1-8. 2004
    ....
  54. pmc Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Patient Prefer Adherence 1:9-17. 2007
    ..Associations of patient beliefs about medication with clinical psychopathology and their life satisfaction were also assessed...
  55. doi Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia
    Bruce J Kinon
    Lilly Bio Medicines, Eli Lilly and Company, Indianapolis, IN, USA
    Neuropharmacology 66:82-6. 2013
    ..Evaluation of the safety, tolerability, and efficacy of LY2140023 is continuing. This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'...
  56. pmc Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Neuropsychiatr Dis Treat 8:113-8. 2012
    ..Current findings are consistent with physicians' stated reasons for switching versus augmenting antipsychotics in the treatment of schizophrenia. Confirmation of these findings requires further research...
  57. pmc Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    Neuropsychiatr Dis Treat 5:47-54. 2009
    ..To better understand sexual dysfunction in patients with schizophrenia and its associations with prolactin and reproductive hormones...
  58. ncbi Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    Psychoneuroendocrinology 28:55-68. 2003
    ..This open-label study was designed to determine the extent of this potential problem in a routine clinical setting...
  59. ncbi Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use
    David A Smelson
    J Clin Psychopharmacol 26:666-7. 2006
  60. ncbi An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia
    Sandra L Tunis
    Health Economics and Outcomes Research, IMS Health, Noblesville, IN, USA
    Curr Med Res Opin 23:97-104. 2007
    ..The objective of this study was to examine the ability of selected variables to predict antipsychotic persistence among patients receiving olanzapine or risperidone as initial treatment...
  61. ncbi An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder
    Franca Centorrino
    McLean Hospital, Harvard Medical School, Boston, MA, USA
    Hum Psychopharmacol 22:455-62. 2007
    ..To determine the effect of intramuscular (IM) olanzapine in severely agitated patients...
  62. ncbi Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia
    Hong Liu-Seifert
    J Clin Psychopharmacol 27:392-4. 2007